
STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma Inc. is leveraging its proprietary XpressCF platform to develop next-generation antibody-drug conjugates (ADCs), notably STRO-004, which exhibits promising preclinical safety data and improved clinical benefits. The company has demonstrated strong execution across its ADC pipeline, suggesting that its engineering approach will result in higher drug exposures and better tolerability compared to current market offerings. The anticipated synergies between STRO-004 and existing therapies could position the product to capture significant market share, thereby enhancing Sutro's overall financial outlook.
Bears say
Sutro Biopharma faces significant challenges in the adoption of its antibody-drug conjugates (ADCs) due to persistent ocular toxicity issues, which hinder oncologists' willingness to engage patients in treatment. The industry expert underscores that approximately 15-20% of patients experience treatment interruptions related to these adverse reactions, leading to delays in care as patients struggle to access specialized ophthalmologic support. Additionally, the complexities surrounding pseudokinases in cancer biology add uncertainty to the efficacy and market potential of Sutro's pipeline, increasing concerns regarding the company's ability to achieve its valuation targets.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares